Table 1. Baseline Characteristics in the Full Analysis Set.
| Baseline characteristics | No. (%) | |
|---|---|---|
| Dual antiplatelet therapy (n = 369) | Alteplase (n = 350) | |
| Age, median (IQR), y | 65 (57-71) | 64 (56-71) |
| Sex | ||
| Men | 256 (69.5) | 240 (68.6) |
| Women | 113 (30.6) | 110 (31.4) |
| Current smokinga | 122 (33.1) | 118 (33.7) |
| Current drinkinga | 59 (16.0) | 56 (16.0) |
| Medical history | ||
| Hypertension | 211 (57.2) | 169 (48.3) |
| Diabetes | 101 (27.4) | 86 (24.6) |
| Prior ischemic strokeb | 82 (22.2) | 77 (22.0) |
| Prior transient ischemic attack | 4 (1.1) | 2 (0.6) |
| Time from onset of symptoms to receipt of assigned treatment, median (IQR), min | 182 (134-230) | 180 (127-225) |
| Time from onset of symptoms to hospital discharge, median (IQR), d | 8 (6-11) | 8 (6-10) |
| INR at randomization, median (IQR) | 1.00 (0.94-1.05) | 0.98 (0.93-1.04) |
| INR >1.2 at randomization | 5/358 (1.4) | 4/344 (1.2) |
| APTT at randomization, median (IQR), s | 31.8 (27.2-36.3) | 31.9 (27.4-35.7) |
| Median APTT >43.5 s at randomization | 15 (4.1) | 13 (3.7) |
| Systolic blood pressure at randomization, median (IQR), mm Hg | 150 (137-166) | 151 (139-162) |
| Median systolic blood pressure >140 mm Hg at randomization | 245 (66.4) | 242 (69.1) |
| Diastolic blood pressure at randomization, median (IQR), mm Hg | 88 (81-95) | 88 (80-95) |
| Median (IQR) diastolic blood pressure >90 mm Hg at randomization | 142 (38.5) | 132 (37.7) |
| Blood glucose level at randomization, median (IQR), mmol/L | 6.3 (5.4-8.3) | 6.4 (5.4-8.1) |
| Blood glucose level >7.0 mmol/L at randomization | 112/316 (35.4) | 121/314 (38.5) |
| NIHSS score at randomization, median (IQR)c | 2 (1-3) | 2 (1-3) |
| NIHSS score of 0 at randomization | 27 (7) | 29 (8) |
| Estimated prestroke function (mRS score) | ||
| No symptoms (score of 0) | 275 (74.5) | 256 (73.1) |
| Symptoms without any disability (score of 1) | 94 (25.5) | 94 (26.9) |
| Presumed stroke caused | ||
| Undetermined cause | 225 (61.0) | 221 (63.1) |
| Small artery occlusion | 87 (23.6) | 79 (22.6) |
| Large artery atherosclerosis | 54 (14.6) | 46 (13.1) |
| Other determined cause | 2 (0.5) | 3 (0.9) |
| Cardioembolic | 1 (0.3) | 1 (0.3) |
| Location of responsible vessele | ||
| Anterior circulation | 283 (76.7) | 279 (79.7) |
| Posterior circulation | 83 (22.5) | 70 (20.0) |
| Anterior and posterior circulation | 3 (0.8) | 1 (0.3) |
| Degree of responsible vessel stenosisf | ||
| Mild (<50%) | 191/246 (77.6) | 185/232 (79.7) |
| Moderate (50%-69%) | 21/246 (8.5) | 15/232 (6.5) |
| Severe (70%-99%) | 14/246 (5.7) | 16/232 (6.9) |
| Occlusion (100%) | 20/246 (8.1) | 16/232 (6.9) |
Abbreviations: APTT, activated partial thromboplastin time; INR, international normalized ratio.
SI conversion factor: To convert glucose to mg/dL, divide by 0.0555.
Current smoking defined as consuming at least 1 cigarette per day within 1 year before the onset of the disease. Current drinking defined as consuking alcohol at least once a week within 1 year before the onset of the disease and consume alcohol continuously for more than 1 year.
Referring only to patients with premorbid modified Rankin Sclae (mRS) score ≤1.
Patients with National Institutes of Health Stroke Scale (NIHSS) scores less than or equal to 5 were eligible for this study; NIHSS scores range from 0 to 42, with higher scores indicating more severe neurological deficit.
The presumed stroke cause was classified according to the Trial of Org 10172 in the Acute Stroke Treatment (TOAST) classification system.
The classification was defined according to the anatomical location of responsible vessel based on the patient’s clinical presentation and neuroimaging, which refers to the clinical features of the Oxfordshire Community Stroke Project classification system.
The degree of stenosis was determined by cerebral vessel examination. The diagnosis was based on the clinician’s interpretation of the clinical presentation and results of the investigations at the time of hospital discharge.